Cargando…
Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC)
PURPOSE: Tuberous sclerosis complex (TSC)-associated renal angiomyolipoma (AML) have a high lifetime risk of acute bleeding. MTOR-inhibitors are a promising novel treatment for TSC-AML, however adequate response to therapy can be difficult to assess. Early changes in MRI signal may serve as a novel...
Autores principales: | Brakemeier, Susanne, Vogt, Lars, Adams, Lisa, Zukunft, Bianca, Diederichs, Gerd, Hamm, Bernd, Budde, Klemens, Makowski, Marcus R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726644/ https://www.ncbi.nlm.nih.gov/pubmed/29232371 http://dx.doi.org/10.1371/journal.pone.0189132 |
Ejemplares similares
-
Sclerotic bone lesions as a potential imaging biomarker for the diagnosis of tuberous sclerosis complex
por: Brakemeier, Susanne, et al.
Publicado: (2018) -
Malignancy of renal angiomyolipoma from tuberous sclerosis complex with TSC2 mutation
por: Huang, Yu-Jing, et al.
Publicado: (2019) -
Percutaneous cryoablation for tuberous sclerosis-associated renal angiomyolipoma with neoadjuvant mTOR inhibition
por: Krummel, Thierry, et al.
Publicado: (2014) -
Recent Advances in Renal Tumors with TSC/mTOR Pathway Abnormalities in Patients with Tuberous Sclerosis Complex and in the Sporadic Setting
por: Kapur, Payal, et al.
Publicado: (2023) -
mTOR Inhibitors in Tuberous Sclerosis Complex
por: Curatolo, Paolo, et al.
Publicado: (2012)